What happened with NRXP today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
NRX Pharmaceuticals combines clinical-stage drug development with a psychiatric-care business. It founded and majority-owns HOPE Therapeutics, whose acquired Dura clinics generate all of the company’s current revenue. Dura provides outpatient behavioral health care, interventional psychiatry and pain-management services. Therapy services bring in most of the revenue, and commercial insurers pay the largest share, alongside Medicare and patients paying directly.
Its drug programs target conditions including suicidal depression. NRX-101 is an oral combination of D-cycloserine and lurasidone; NRX-100 and KETAFREE are preservative-free ketamine formulations. The company has a commercialization agreement with Alvogen for NRX-101, but has not generated drug-product revenue. Its candidates cannot be sold until they receive the required regulatory approvals. NRX-100 also faces U.S. controlled-substance oversight because it contains ketamine.
The clinic business depends on insurers’ coverage and reimbursement terms. Drug development and continued operations still depend on equity or debt financing rather than substantial drug sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Johnson & Johnson sells SPRAVATO to treat treatment-resistant depression, directly competing with NRX Pharmaceuticals’ ketamine formulations and ketamine-based psychiatric care for these patients.
Axsome Therapeutics sells AUVELITY for major depressive disorder, competing for psychiatric treatment spending with the depression medicines NRX Pharmaceuticals is developing. Watch AUVELITY sales specifically: Axsome’s other marketed drugs treat sleepiness and migraine, not depression.
Alto Neuroscience is developing drugs for treatment-resistant depression, bipolar depression and schizophrenia, overlapping NRX Pharmaceuticals’ psychiatric pipeline and intended patients. Its clinical data in these patient groups matter more to this rivalry than sales; Alto has not yet built a commercial sales organization.
Helus Pharma is developing depression treatments that act on serotonin receptors, competing for patients with NRX Pharmaceuticals’ ketamine-based therapies and psychiatric services. Watch its clinical development rather than drug sales: its programs remain investigational, and it does not expect product-sale revenue for the foreseeable future.
Xenon Pharmaceuticals’ investigational azetukalner targets major depressive disorder and bipolar depression, overlapping NRX Pharmaceuticals’ depression drug programs. Its Phase 3 results in those two conditions are the relevant competitive signal, rather than results from its epilepsy trials.
LB Pharmaceuticals develops LB-102 for schizophrenia and bipolar depression and explicitly names NRX Pharmaceuticals as a bipolar-depression competitor. Watch LB-102’s bipolar-depression progress separately from its Phase 3 schizophrenia program; that is where LB identifies the direct rivalry.
Neumora Therapeutics is developing depression drugs that compete with NRX Pharmaceuticals’ efforts to introduce new depression treatments. Clinical development and regulatory progress are what to watch: Neumora had no approved or commercialized products and no product-sales revenue through December 31, 2025.
Minerva Neurosciences is developing roluperidone for schizophrenia’s negative symptoms, competing in a treatment market NRX Pharmaceuticals also targets. Watch roluperidone’s clinical and approval progress specifically for those symptoms; Minerva had no approvals to sell its candidates as of December 31, 2025.
MapLight Therapeutics is developing ML-007C-MA, a medicine combining two agents in fixed doses, for schizophrenia, competing in one of NRX Pharmaceuticals’ target treatment markets. Watch results from its Phase 2 ZEPHYR schizophrenia trial, which MapLight had expected to report in the third quarter of 2026.
Axsome Therapeutics, Inc earningsAXSM
Johnson & Johnson’s report will show how SPRAVATO is selling, as the treatment for treatment-resistant depression competes with NRX Pharmaceuticals’ ketamine-based care for patients and treatment spending.
Focus on Johnson & Johnson’s disclosed SPRAVATO sales, not its overall results. Growth would show patients and payors are taking up this competing treatment, potentially making it harder for NRX Pharmaceuticals to win the same patients and treatment spending; weakness would indicate softer commercial demand for this marketed option, but would not prove NRX’s candidates will succeed.
NRX Pharmaceuticals, Inc. earningsThis company
NRX Pharmaceuticals’ report will show whether its clinics are bringing in more patient-service revenue and how much cash its drug trials continue to consume.
Read patient-service revenue alongside cash used in operating activities, and compare research and development and administrative expenses. Rising service revenue with slower cash use would suggest the clinic business is expanding while easing the funding burden; little revenue growth with continued cash outflow would leave clinical development more reliant on outside capital. The prior-year period had no patient-service revenue, so consider when acquired clinic operations entered the results before judging the comparison.
